이전|다음

FBXL6 및 KRASG12D에 대한 통찰을 통한 간세포암종의 분자 상호작용 및 종양 형성 해독

  • role： First author第一作者
  • Affiliation：

    Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, China

Qiang Cai1,  
  • role： Corresponding author通信作者
  • Affiliation：

    Institute of Chemistry, University of Silesia in Katowice, 41-500 Chorzów, Poland

  • Email：tanminul-haque-shubra.quazi@us.edu.pl
  • Introduction：*tanminul-haque-shubra.quazi@us.edu.pl; shubhro.du@gmail.com
Quazi T. H. Shubhra2*

추상적인

키워드

hepatocellular carcinoma;F-box and leucine-rich repeat 6 (FBXL6) activation;Kirsten rat sarcoma (KRAS)G12D mutation;Mitogen-activated protein kinase (MEK)/mammalian target of rapamycin (mTOR) pathway;metastasis

References

  1. 1..
    Xiong HJ, Yu HQ, Zhang J, Fang L, Wu D, Lin XT, et al. Elevated FBXL6 activates both wild-type KRAS and mutant KRASG12D and drives HCC tumorigenesis via the ERK/mTOR/PRELID2/ROS axis in mice. Mil Med Res. 2023;10(1):68.
  2. 2..
    Shubhra QTH. RARRES2’s impact on lipid metabolism in triple-negative breast cancer: a pathway to brain metastasis. Mil Med Res. 2023;10(1):42.
  3. 3..
    Zaman R, Cai X, Shubhra QTH. Hyperthermia-embolization-immunotherapy: a potent trio in advancing cancer treatment. Trends Mol Med. 2023;29(12):976–8.
  4. 4..
    Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6(1):386.
  5. 5..
    Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019;12(1):71.
  6. 6..
    Guo K, Xiao N, Liu Y, Wang Z, Tóth J, Gyenis J, et al. Engineering polymer nanoparticles using cell membrane coating technology and their application in cancer treatments: opportunities and challenges. Nano Mater Sci. 2022;4(4):295–321.

더 읽기

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website